Mid-Atlantic BioTherapeutics, Inc. Launches $5 Million Regulation D 506(c) Funding Round to Support Clinical Program Acceleration and Expand the Company’s Global Reach and Market Presence
DOYLESTOWN, Pa., Oct. 15, 2024 /PRNewswire/ — Mid-Atlantic BioTherapeutics, Inc. (the “Company“), a clinical-stage biotechnology company specializing in cutting-edge immunotherapies and central nervous system (“CNS“) disorder treatments, today announced the commencement of a fundraising round …